VGXI, Inc. Names Jeff Whitmore as New Chief Commercial Officer
Leading plasmid DNA CDMO VGXI, Inc. announces the appointment of Jeff Whitmore as its new Chief Commercial Officer.
VGXI Inc., a distinguished Texas-based Contract Development and Manufacturing Organization (CDMO) specializing in the production of plasmid DNA and RNA biopharmaceuticals, is pleased to announce the appointment of Mr. Jeff Whitmore as Chief Commercial Officer (CCO). With over 25 years of experience in the biotechnology industry, Whitmore brings valuable expertise to VGXI’s corporate team, having previously served as CCO for Genezen and VP of Commercial Operations at TriLink BioTechnologies.
In his role as CCO, Whitmore will drive the commercial team’s efforts to support VGXI’s newly opened headquarters and state-of-the-art production facility located at Deison Technology Park in Conroe, TX. The facility expansion is part of VGXI’s overall transition from a boutique manufacturing organization into a full-scale commercial operation, catering to the growing demands of the vaccine, immunotherapy, and cell and gene therapy industries. VGXI has long been recognized for its exceptional quality in DNA products and services, and under Mr. Whitmore’s leadership, the company aims to fuel rapid growth, consolidate its global brand positioning, and expand its client base.
“Jeff is a skillful strategist with a track record of success in product value positioning and leading transitional growth, as demonstrated during his time at TriLink,” said VGXI’s President and CEO, Young Park. “We are excited for him to join the VGXI team.”
This announcement follows the recent appointment of Mr. Jim Smith as Chief Accounting Officer, highlighting VGXI’s commitment to fostering rapid business expansion and the development of commercial services.
ABOUT VGXI, INC.
With over 20 years of experience VGXI, Inc. is a leading provider of plasmid DNA manufacturing and development services. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and highly experienced development team. VGXI, Inc. is a GeneOne company.
ABOUT GENEONE LIFE SCIENCE
GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) headquartered in Seoul, South Korea is an international biotechnology company and a leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. GeneOne has recently expanded into the manufacture and development of mRNA. GeneOne has maintained a focus on vaccines against emerging infectious diseases to address global needs, including in resource challenged regions. Its small molecule portfolio of immunomodulators address diseases such as prevention of upper respiratory bacterial and viral diseases, and treatment of autoimmune and inflammatory diseases. GeneOne has three products against COVID-19 in clinical development: GLS-5310 DNA vaccine (Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection (Phase II), and GLS-1027 to prevent the inflammation and clinical worsening for those infected with COVID-19 (Phase II). For more information, visit http://www.genels.com.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.
Click here to view the official release on PRWeb.
Media Contacts:
Christy Franco, Ph.D.
Director, Business Development
